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Since the inception of Extracorporeal Membrane Oxygenation (ECMO) in the early
1970’s, technological advances and increased understanding and implementation of ECMO
protocols have produced exponentially better outcomes. With improved outcomes, use of
ECMO has dramatically risen in the last several decades. The purpose of this study is to define
the modalities of ECMO and their purposes, as well as potential complications and
contraindications. Furthermore, research was conducted into determining important factors in
patient outcomes such as patient characteristics, readmission rates, and success of the therapy.
Patient data was scrutinized to determine if any categorical particularly affected the overall costs
and outcomes of ECMO patients. Moreover, odds of readmission were calculated to measure the
efficacy of ECMO as a therapy.
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ECMO is an everchanging modality of therapy and as we continue to experience the
benefits of its efficacy, we can better execute care plans, manage concurrent treatments, and
offer better encompassing healing improving patient satisfaction and hospital profits. Research
demonstrates that prompt assessment and rapid implementation of ECMO therapy are vital to a
patient’s positive outcome. It is certain that as the wellness of the American population
continues to diminish that we will undoubtedly witness an increasing utilization of ECMO.
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1
1.1

CHAPTER I: INTRODUCTION

Background
Extracorporeal membrane oxygenation, or ECMO, is a therapy that was first utilized in

the adult patient population in the 1970’s. It has developed into an established life-support
technique for the managing of various life-threatening cardiac and/or pulmonary conditions
(Abrams et al., 2014). ECMO effectively replaces the function of the native heart and lungs,
allowing them to recuperate and rest. For those who are unable to recover, ECMO may be used
as a bridge to destination therapy, a permanent assist device, or transplant. Patient’s requiring
support from ECMO are cared for in a hospital’s intensive care unit (ICU). ECMO may be
indicated in all patient populations; neonatal, pediatric, and adult. ECMO has been proven to be
an effective therapy among neonates, with survival rates up to 84%, but complications and
mortality rates among adults following treatment are high. Survival among adult patients at
discharge have been reported to vary between 33% and 53% (Mao et al., 2016).
Prior to the publication of the CESAR Trial in 2008, (Thalanany et al., 2008) the number
of ECMO cases reported within the United States expressed diminutive variation. In 2001, 309
cases were reported, while an analogous 318 were recorded in 2007. Mao et al., (2016) stated
that following the CESAR Trial’s release in Quarter 1 of 2008, a 646% increase in ECMO
utilization occurred. By 2011 the number of cases soared to 1,995. Additionally, beginning in
Quarter 2 of 2008, it was observed that those who received ECMO as treatment were comprised
of an older, sicker patient population. Patients treated with ECMO following Quarter 1 were
more likely to have two or more comorbidities (Mao et al., 2016).
Those requiring ECMO will experience one or more of the following conditions: 1) Their
lungs cannot adequately oxygenate the tissues even when administration of therapeutic oxygen
11

occurs. 2) The patient is retaining carbon dioxide and cannot clear increasing amounts of carbon
dioxide or CO2 in the body, and 3) the heart is unable to effectively perfuse the major organs, or
tissues at the periphery of the body. These conditions may arise following an allergic reaction,
cardiac arrest, infection, status post cardiac surgery, or even trauma (Abrams et al., 2014).
Careful consideration should be given before initiating ECMO. Physicians must
approach each case with an open mind, and most importantly, be realistic in their expectations of
the outcome. It is essential that physicians consider patient comorbidities, patient prognosis, and
weaning strategies before endeavoring into the support of an ECMO patient (Ramanathan et al.,
2015).
Contraindications for the initiation of ECMO are scarce but do exist. According to the
Extracorporeal Life Support Organization (ELSO) compliance concerns brought on by cognitive,
economic, or social limitations must be ascertained and assessed. Active bleeding, such as seen
in a hemorrhagic cerebral vascular accident, the gastro-intestinal tract, or perhaps a
retroperitoneal bleed should automatically negate the ability to treat the patient with ECMO.
Additionally, chronic organ dysfunction such as cirrhosis, emphysema, and renal failure do not
make for the best candidates. Any persons who are not suitable candidates for durable
mechanical support, transplantation, or have received prolonged cardiopulmonary resuscitation
(CPR) without adequate tissue perfusion and are determined to have unrecoverable cardiac
function should not be considered as viable ECMO candidates. (ELSO, 2021)
ECMO may be implemented on a temporary basis, being anywhere from a few hours, up
to several months. Duration of the treatment is dependent on the etiology and severity of the
diagnosis, as well as the patient’s response to the treatment. Research shows that early initiation
and advanced techniques can dramatically improve the number of positive outcomes. Rosenfeld
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et al. (2017) found that early initiation is subject to improve the patient’s prognosis. Bosarge et
al. (2015) similarly concluded that ECMO should be considered early to effectively lessen
mortality rates.
There are two types of ECMO; veno-arterial (VA) ECMO can be used for cardiac and
pulmonary support, while veno-venous (VV) ECMO is only used for pulmonary support.
VA-ECMO provides cardiopulmonary support for the patient by directing the patient's blood to
flow through the extracorporeal circuit and bypassing the patient's native heart. A large
indwelling cannula takes blood out of the vena cava, into a centrifugal pump, then into an
oxygenator, through a second cannula and returns it into the patient’s body via a large artery.
This modality allows for both the gas exchange and cardiac output to originate from the ECMO
circuit. This provides the necessary functions of both the heart and the lungs, allowing for the
native organs to experience a significantly reduced workload (Brogan & Annich, 2018).
VV-ECMO only provides pulmonary support to the patient. In this type of ECMO, the
patient's heart must still function well enough to adequately meet the body's demands. Like VAECMO, two cannulas are placed into the patient, and their blood utilizes the same circuit.
Conversely, oxygenated blood is returned to the venous system, in proximity to the heart. The
oxygenated blood is returned into the venous system allowing the oxygenated and nutrient rich
blood to follow through its natural pathway into the native lungs, heart, and circulated
throughout the body (Brogan & Annich, 2018).
ECMO is initiated by a cardiothoracic or vascular surgical team. Initiation may take
place in a variety of settings, including, but not limited to: the Emergency Room, (ER), ICU, or
the Operating Room (OR) (Brogan et al., 2017). Once initiated, monitoring the patient is
extremely labor intensive and requires specialized training. Near constant assessment of the
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ECMO circuit, hemodynamics, and patient response is necessary. Regular arterial blood gases
(ABGs) and activated clotting time (ACT) tests are mandatory. ABGs may be drawn from
various locations and can be employed to yield an assortment of essential data used to determine
efficacy of the ECMO circuit, as well as current patient status. ACTs are required to determine
the efficiency and current levels of the patient’s anticoagulation therapy. Without appropriate
anticoagulation, in a short period of time, the ECMO circuit will begin to collect fibrin and
initiate the clotting cascade in which substantial blood clots may be formed. These blood clots
will continue to grow, causing the ECMO circuit to experience an increase in resistance, and
ultimately a decrease of flow. If flow is reduced enough, or completely stopped, this can either
directly, or indirectly result in the patient’s death. Conversely, excessive anticoagulation can
cause severe hemorrhaging and in due course, the exsanguination of the patient (Brogan &
Annich, 2018).
Common risks of ECMO include bleeding, infection, kidney failure, and stroke.
Anticoagulation management of the ECMO patient is key (Nichani, 2011). There must be
enough anticoagulation to prevent a threat to the circuit, and yet be conservative enough to
minimize the inevitable bleeding. Bleeding may occur from the cannula insertion locations, or
cites of surgical incision, as well as any damaged tissue incurred from trauma. (Abrams et al.,
2014) Aubron et al. (2016) stated that bleeding incidents occurred in 60% of ECMO cases
related to a mortality. These incidents are defined by ELSO as administration of two or more
units of red blood cells within 24 hours, or a 2 gm/L drop in hemoglobin within the same
timeframe (Brogan et al., 2017).
A primary obstacle that may negatively influence ECMO outcomes is infection. In a prior
cohort study that encompassed over 20,000 neonatal, pediatric, and adult ECMO patients, the
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frequency of new infection during adult ECMO was 30.6 infections per 1000 ECMO days in VA
ECMO patients. VA-ECMO patients were found to have a higher risk for infection than VV
ECMO patients (Menaker et al., 2019). In both VA and VV-ECMO, patients require large bore
indwelling cannulas that are not easily exchanged if they become infected. ECMO patients also
frequently require central venous catheters (CVC) and arterial catheters. CVCs are required for
the administration of vasoactive medications while arterial catheters are needed for
hemodynamic monitoring; both of which increase bloodstream infection (BSI) risk. According
to Menaker (2019), several additional smaller studies have specifically explored the incidence of
BSI during ECMO and found the occurrence to be relatively small. One study of 16 VV-ECMO
patients described the incidence rate of BSI as 19 infections per 1000 ECMO days. In a different
study, 47 adult ECMO patients demonstrated an occurrence of BSI as 27.7% and stated that
nearly 50% of patients with BSI had bacterial colonization of their ECMO cannulas after
removal. Lastly, in a study encompassing 121 VV-ECMO patients, the incidence of BSI was
17% during the first 6 ECMO days. In this study, allogeneic blood transfusion was denoted as
an associated and increased BSI risk (Menaker, 2019).
Acute kidney injury (AKI) that develops during ECMO has been found to be associated
with tremendously poor outcomes. AKI and its complications such as volume overload and
azotemia commonly occur in ECMO patients. Research shows that more than 75% of the
patients requiring ECMO therapy develop AKI (Chen et al., 2014). Chen et al. (2014) continues
to state that renal replacement therapy (RRT) is found to be required in approximately 50% of
these patients. The management of patients with AKI is principally supportive with RRT
indicated for patients with severe kidney injury.
Neurological complications such as intracranial hemorrhage (ICH), ischemic stroke, and
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seizure, are risks which can dramatically affect outcomes, as well as associated costs (Nasr &
Rabinstein, 2015). These complications can be attributed to low level hemolysis (Saeed et al.,
2019). Saeed et al found a direct correlation between hemolysis and ischemic stroke. Hemolysis
occurs due to a variety of factors. Although much less destructive than its predecessor the roller
head pump, centrifugal pumps still attribute to hemolysis. Additionally, the choice of cannula
size is found to be at fault, increasingly more so when combined with elevated flow rates for
long periods of time. Furthermore, blood product usage requirements are typically higher in VAECMO patients. Subsequently, the introduction of blood products may also contribute to
hemolysis (Appelt et al., 2020).
Members of the ECMO team include a variety of doctors from a vast number of
specialties; cardiothoracic and/or vascular surgeons, infection control, nephrology, neurology,
pharmacy, pulmonology, and radiology. Additional specially trained staff including Intensivists,
Nurses, Perfusionists, and Respiratory Therapists are also required. Extra ancillary staff
including hospital laboratory and x-ray technicians, nutrition specialists, and occupational
therapist’s services are also essential. Coordination among these specialties is vital and can
dramatically affect the patient’s outcome (Brogan et al., 2017).
1.2

Problem Statement
ECMO is an extremely costly therapy. In 1993, it was said that the cost of ECMO was

between $5,000 and $10,000 USD per day (Hayden, 1993). Considering an average inflation
rate of 2.15% per year, in 2020, that would be approximately $9,060 to $18,119 dollars per day.
This may prove to be a low estimate as research stating the average daily costs of ECMO in 2013
fell between $3,000 and $20,000 per day (Zangrillo et al., 2013). It was specified that the three
most common complications of patients supported by ECMO were AKI (32.8%), BSI (31.8%),
16

and bleeding (27.8%). They reported that an average hospitalization cost of an ECMO patient
with zero complications totaled $53,470 (Dhaija et al., 2021). A single complication nearly
doubled that cost to $97,560. Two complications further increased the cost to $139,035, while
three complications increased the expenditures to $162,284 (Dhamija et al., 2021). It was
reported that by having one complication the median hospital costs were increased by 24%,
while two complications increased costs by 38%. Furthermore, a single complication was
related to an increase of mortality odds by 165%, while two or three complications increased
those odds by 375% and 627% respectively (Dhamija et al., 2021).
According to the 2019 ELSO International Survey Report, in 2018 there were 19,482 adult
pulmonary (VV-ECMO) cases. Of those, 13,453 patients, or 69% survived extracorporeal life
support (ECLS). Furthermore, 11,565, or 59% survived to transfer, or discontinuation of
professional care. Subsequently, adult cardiopulmonary (VA-ECMO) cases equaled 19,627
while 11,628, or 59% survived ECLS, while 8,381 or 42% survived to discharge or transfer
(ELSO, 2019). Current nationally representative studies of ECMO and their costs, disease
processes, and mortality rates are scarce.
1.3

Study Aims
We propose, a descriptive retrospective cohort study of ECMO patients in the state of

Florida to quantify the disease process and mortality outcomes relating to ECMO. In addition to
etiology and mortality estimates, the current study also proposes to perform a economic analysis
of the direct costs of hospital care. This will be estimated in a hospital cost analysis of average
total hospital cost and cost per day based on Florida hospital billing data from 2018.

17

2
2.1

CHAPTER II: LITERATURE REVIEW

Background and History of ECLS

Extracorporeal Life Support (ECLS) experienced its first success in 1971, in a patient
experiencing Acute Respiratory Distress Syndrome (ARDS) (Brogan et al., 2017). ECLS
originated from within the operating room, an evolution based on the same constructs and
principles as cardiopulmonary bypass. Its inception was derived as a support therapy for ailing
cardiac and pulmonary patients in the ICU (Brodie et al., 2019). Rudimentary varieties of ECLS
established in the early1970s were utilized for decades prior to being principally disregarded due
to a shortage of convincing indications for their safety and efficacy.
Although, first effectively utilized in a patient with ARDS in the early 1970s, initial
eagerness for ECLS in acute respiratory failure was dampened by two negative randomized
clinical trials which were published in 1979 and 1994 respectively.
In 1979, the study compared VA-ECMO with aggressive mechanical ventilation versus
mechanical ventilation alone, rather than VV-ECMO combined with protective ventilation
strategies. This study was halted prematurely due to a struggle with participant recruitment.
Ultimately, 90 patients were randomized into two groups, one consisting of 42 (46.7%)
participants of whom were relegated to the ECMO arm of the study. It was noted that the 30-day
survival rate was equally substandard in both groups at less than 10%. While ECMO could have
potentially benefited these participants, any benefits may have been counterbalanced by the
rudimentary equipment and lacking expertise of that era. These conditions may have led to
serious complications, such as bleeding, infections, and neurological deficits. Furthermore, most
enrolling facilities had little to no experience with the technology (Brodie et al., 2019).
Brodie et al. (2019) continues explaining that the concept of ventilator induced lung
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injury (VILI) was not well understood or accepted as a concern at the time. This
misunderstanding of the ventilator strategy was evident and not appreciably addressed in the
ECMO arm of the study.
In 1994, Morris et al randomized 40 patients with severe ARDS into two interventions: 1)
pressure controlled inverse ratio ventilation followed by veno-venous extracorporeal carbon
dioxide removal (ECCO2R), and 2) conventional mechanical ventilation. This trial prematurely
ceased due to recognizable futility (Morris et al., 1994). There was no substantial variance in
survival between the two groups. However, it was noted that a significant increase in bleeding
occurred within the extracorporeal group. The obvious differences in the necessity of blood
product use were contributory partially to the aggressive anticoagulation mandatory for the
thrombogenic circuit component surfaces used during that period (Brodie & Bacchetta, 2011;
Brodie et al., 2019).
A turning point in the utilization of ECMO occurred in 2009 due to the convergence of
two major events; the publication and interest in the CESAR study, and the prevalent use of
ECMO for patients diagnosed with influenza associated ARDS during that year’s pandemic
(Brodie & Bacchetta, 2011). The CESAR study was a logical trial of 180 adults with severe
acute respiratory failure randomized into two groups. First, a conventional style management
within any of the 68 facilities noted, or secondly, transfer the patient to a single ECMO center in
the United Kingdom, where initiation of ECMO and use of a protocol were administered if
required. It was reported that ultimately, only 76% of the patients in the ECMO arm of the study
received ECMO treatment (Thalanany et al., 2008).
Additionally, Thalanany et al. (2008) goes on to explain the CESAR trial was a pragmatic
trial in which patients in the control group were not mandated to receive low volume/pressure
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ventilation, and that it was reported that only 70% did at any point during the study. Brodie et al.
(2019) notes that by not providing standard ventilation for all patients in the control group, a
clearly biased result favors the outcomes towards those in the intervention (ECMO) cohort,
making the 16% total decrease in the principal end point of death, or severe disability at six
months, reported as survival to six months without disability (64% vs 47%; relative risk [RR]
0.69 [95% CI, 0.05-0.97]: P = .03) quite difficult to construe (Brodie et al., 2019). Nonetheless,
adult ECLS advanced noticeably with improvement in biocompatible surfaces, cannulae options,
membrane oxygenators, and pumps (Brogan et al., 2017).
Throughout the last decade or so, the sum of patients supported with VA-ECMO has
experienced an exponential increase. An association has been identified signaling a relationship
between the degree of a hospital’s ECMO practice with patient outcomes. The results indicate
the need for understanding the minutia of ECMO initiation, management, and monitoring
(Krishnan & Schmidt, 2019).
Use of ECLS has substantially increased at times far outpacing the evidence justifying its
use. An increasing evidence base now supports greater use of ECLS for adult patients in
respiratory failure (Brodie et al., 2019). Nevertheless, advances in efficacy, quality and
technology sparked a renewed awareness, and vigor in the use of ECLS. These improvements
have provided rapid growth in understanding and utilization of ECLS as a potential lifesaving
strategy (Grant et al., 2018).
According to Menaker et al. (2019) implementation of adult ECMO has increased with
nearly 10,000 adult ECMO runs reported in 2017. Mortality rates remain comparatively high at
40% and 60% recorded for VV- and VA-ECMO respectively. This is due in part by serious
complications realized throughout ECMO.
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ELSO reported the number of adult cardiac ECMO runs increased 1,180% in the last
decade. This increase is demonstrated from less than 200 recorded runs between 1997 and 2007,
to over 20,000 in 2020. (Guglin et al., 2019, ELSO, 2021) Likewise, the number of ECMO
centers only increased by 15% between the years of 1996 and 2006, beginning at 115 and
totaling 131. Guglin et al. (2019) reported an increase of 133% in ECMO centers from 131 in
2006 to 305 in 2016.
2.2

Nomenclature of ECLS

Extracorporeal terminology for respiratory and cardiac failure support is denoted by
many often with overlying and indefinite terms. An international consensus statement recently
clarified the nomenclature (Conrad et al., 2018). Extracorporeal life support (ECLS), an oftenmisconstrued term, is separated in to two modalities: 1) extracorporeal membrane oxygenation
(ECMO) and, 2) ECCO2R (Brogan et al., 2017).
ECMO includes the modalities of VA-ECMO, VV-ECMO, and extracorporeal
cardiopulmonary resuscitation (ECPR). ECMO provides sufficient blood flow rates for either
respiratory gas exchange support (VV-ECMO) or circulatory support (VA-ECMO) (Brodie et
al., 2019).
VA-ECMO is used when cardiac and full circulatory support is required,
characteristically only for rescindable etiologies of acute heart failure, or as a bridge to
transplant. Each method has its own unique set of complications, contraindications, as well as
indications (Grant et al., 2018).
VA- ECMO is the only modality capable of providing comprehensive circulatory support
providing both respiratory and hemodynamic support to the patient (Guglin et al. 2019).
Compared with other temporary mechanical circulatory support devices used to support patients
21

with refractory cardiogenic shock, VA-ECMO addresses both right ventricular and left
ventricular dysfunction, systemic oxygenation, and acid base balance via modulation of the
partial pressure of CO2. The circuit configuration permits the withdrawal and pumping of
desaturated blood from the right atrium or a central vein, with the non-pulsatile pump outflow
directed toward the membrane oxygenator. Gas exchange then occurs within the oxygenator and
the blood is then reinfused directly into the arterial system to provide partial or complete cardiac
and/or circulatory support. The degree of respiratory support is variable upon the efficacy of the
patient’s native lungs. The blood is then redistributed to the body via an outflow cannula which
is placed into a systemic artery (Brodie et al., 2019, Brogan et al., 2017).
Brogan et al. (2017) continues to describe that during VA-ECMO, the physiological
functions of both the native heart and lungs are supplemented by artificial organs, either in part,
or entirely (Brogan et al., 2017). VA ECMO is used when cardiac and/or circulatory support is
required, characteristically for reversible etiologies of acute heart failure, or as a “bridge to
transplant” (Guglin et al., 2019).
Ironically, both VV- and VA-ECMO can be used to treat refractory acute respiratory
failure, conversely, VV-ECMO is not capable of providing adequate oxygen delivery to the body
or its organs (Krishnan & Schmidt, 2019). Brodie et al. (2019) describes the standard rate at
which VV-ECMO blood flow rates are typically delivered at one to three liters per minute, while
VA-ECMO flows are generally three to seven liters per minute.
Grant et al. (2018) noted that VV-ECMO is the designated practice for supporting and
even replacing pulmonary function in conditions like acute respiratory failure. Continuing, the
study states that VV-ECMO is indicated for acute and reversible causes of respiratory failure
once each tactic to achieve lung protective mechanical ventilation has been exhausted. The most
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common pathology for which VV-ECMO is indicated, is the broad and unspecific classification
of direct or indirect lung injury resulting in ARDS. The most common examples of these
ailments are aspiration, pneumonia, sepsis, and traumatic hemorrhagic shock with massive blood
product transfusions. Less common causes include drug overdose, near drowning, pulmonary
embolus, and transfusion related acute lung injury (TRALI).
Extracorporeal cardiopulmonary resuscitation (ECPR) is described as the application of
ECMO therapy in patients where conventional cardiopulmonary resuscitation (CPR) measures
are ineffective in achieving a reoccurrence of natural circulation. The key purpose of ECPR is to
reestablish the body’s organ perfusion and native gas exchange during ordinary circulation
(Brogan et al., 2017).
ECPR offers a protracted timetable for the delivery of required interventions to reclaim
adequate native circulation. As one can understand, ECPR is a time sensitive, complex
intervention that requires clearly defined roles and team synergy. ECPR can be implemented in
patients who are experiencing cardiac arrest, both inside and outside the hospital (Brodie et al.,
2017). Regardless of the local of its occurrence, ECPR should be considered and initiated before
21 minutes of failed conventional resuscitation efforts (Guglin et al., 2019). Evidence favoring
ECPR over conventional CPR is due to a survival benefit of the increased number of intact
neurological outcomes over conventional CPR. Neurological outcomes have also been shown to
directly correlate to judicious ECPR initiation (Richardson et al., 2021).
With exponential improvements in extracorporeal technology, ECCO2R has
rematerialized as a probable management stratagem for certain subgroups of patients
experiencing respiratory failure. The capability to execute ECCO2R at considerably low blood
flow rates while employing smaller cannula then are essential for ECMO, could significantly
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change the approach to hypercapnic respiratory failure. Brodie et al. (2019) went as far as to
effectively compare ECCO2R to an equivalent of dialysis for the lung. However, studies
demonstrating a benefit on meaningful clinical results and tolerable risk are required before such
strategy can be suggested for regular clinical use (Brogan et al., 2017).
ECCO2R is most physiologically beneficial for those patients suffering from hypercapnic
respiratory failure, like those with an acute exacerbation of Chronic Obstructive Pulmonary
Disease (COPD). Those who have either failed, or are failing noninvasive ventilation to avoid
endotracheal intubation, or those who have already been intubated may be liberated sooner from
invasive mechanical ventilation. Risk of ventilator associated pneumonia (VAP) is reduced in
hypercapnic patients by minimizing pulmonary hyperinflation by the ability to reduce not only
minute ventilation, but also sedation during mechanical ventilation (Brodie et al., 2019).
Brodie et al. (2019) continues explaining the intent of ECCO2R is to eradicate exceedingly
high carbon dioxide (CO2) levels, which can be done by utilizing comparatively lower blood
flow rates, which in turn will not provide significant oxygenation. For example, gas exchange
support via an extracorporeal circuit at relatively low blood flow rates typically less than 1.5 liter
per minute, which may be adequate for meaningful carbon dioxide removal, but not complete
oxygenation which would require blood flow rates between three and five liters per minute
(Gravlee et al., 2016).
2.3

Contraindications for Use of ECLS

Presently, the only absolute noted contraindication for the initiation of ECMO therapy is
for any anticipated non-recovery lacking a strategy for viable decannulation. This state could be
due to the disease process itself, or multi-organ failure whereas there is no option for organ
transplantation. At times, it may be unknown whether the patient is a candidate for transplant
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when the choice to initiate ECMO needs to be made. Under these circumstances, ECMO may be
initiated under the pretext of “bridge to decision” (Tonna et al., 2021).
Contraindications acknowledged for VA-ECMO comprise severe irrevocable noncardiac
organ failure restricting survival. Examples of this would be a substantial anoxic brain injury, or
metastatic cancer. Additional instances may be the presence of aortic dissection, or permanent
cardiac failure without the possibility of the implantation of a ventricular assist device (VAD).
Severe coagulopathies, or a contraindication to anticoagulation, as well as advanced liver
disease, amputated limbs, extreme obesity, and limited vascular access may preclude ECMO
therapy treatment. Predicators of mortality may also be considered. An incomplete list may
include age, COPD, decreased baseline cardiac function, decreased urine output, gender,
increased lactate concentration, and renal disease (Guglin et al., 2019).
The only absolute contraindication to the use of ECLS for respiratory failure, or VVECMO, is an irreversible underlying process when the patient is not a candidate for lung
transplantation. Proposed relative contraindications, such as moribund state, are mostly common
sense and relate to poor overall prognosis. Difficult vascular access may also rarely negate the
use of ECLS (Brodie et al., 2019).
2.4

Indications for Use of ECLS

The key to success of ECMO is in the principle of identifying a strategy as the bridge to
decision, recovery, or transplant. ECMO is not a cure for the underlying ailment; it simply is a
vessel which offers time for the patient to heal, or for the providers to discover a viable longterm solution such as a VAD or transplantation. VA-ECMO insertion is typically done to: 1)
provide adequate circulatory support while the heart convalesces, either spontaneously, or with
treatment, and 2) allow the team to determine potential reversibility of end organ injury. This
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may be commonly seen after a substantial myocardial event to attain a period of temporary
stability until a more final pump support or cardiac replacement therapy is deployed (Guglin et
al., 2019).
Guglin et al. (2019) continues, stating, that indications for VA-ECMO are continuing to
develop. Over the past decade, primary indications for VA-ECMO have shifted from postcardiotomy shock to multifactorial cardiogenic shock and/or cardiac arrest. The reported number
of post-cardiotomy shock patients supported with VA-ECMO diminished from 56.9% to 37.9%
in 2002 and 2012 respectively.
2.5

Special Considerations for Inititating ECLS

It is reported that a lack of strategy resolution, or a potential to recover should discourage
ECMO initiation (Brogan et al., 2017). Consideration before patient cannulation should include
various factors concerning the patient’s condition. Cardiac arrest, cardiogenic shock, failure to
wean off cardiopulmonary bypass, refractory ventricular tachycardia, and right ventricular failure
prove pertinent to possible patient outcomes (Guglin et al., 2019).
VV ECMO should be considered in patients with acute, reversible, and severe respiratory
failure that are obstinate to optimum medical management. The rationale for the use of VVECMO includes: 1) having to intensify systemic oxygenation and CO2 removal, and 2) evading
injurious mechanical ventilation (Tonna et al., 2021). It has been reported that an increasing
period of mechanical ventilation prior to ECMO is linked with a waning mortality rate following
ECMO. Optimal therapeutic management should be hastily and momentously executed, not
delaying the initiation of ECMO therapy when properly indicated (Brogan et al., 2017; Brogan &
Annich, 2018).
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2.6

Patient Selection

One of the principal trials for appropriately utilizing ECMO therapy is proper patient
selection. ELSO suggests that ECMO should be considered when the patient’s mortality risk
reaches 50%, while indicated if the mortality risk is perceived to be 80% or higher (Brogan et al.,
2017; Brogan & Annich, 2018). ELSO recommend using an amalgamation of the Murray Score
and PaO2/ FiO2 ratio to determine mortality risk (Grant et al., 2018).
Tonna et al. (2021) clarifies that when assessing adults with acute respiratory failure for
ECMO, it is imperative to establish that the etiology of respiratory failure is refractory to
conventional treatments. ECMO support is often attempted after unsuccessful efforts at
numerous rescue therapies, such as prone positioning, alveoli recruitment maneuvers, and use of
nitric oxide, either singularly, or in any combination thereof (Romano et al., 2017).
Additionally, patient conditions should be considered reversible, and free of all contraindications
for the therapy (Grant et al., 2018).
In the case of an irreversible disease process, end stage pulmonary disease patients may
be considered suitable candidates for ECMO, if employed as a bridge to lung transplant (Tonna
et al., 2021).
According to Brogan and Annich (2018), patient selection necessitates an
interdisciplinary consensus amongst an anesthesiologist, cardiothoracic surgeon, ECLS
specialized intensivist, primary care/attending physician, and any other physicians directly
involved in the patient’s care.
ECMO can be an extremely effective therapy, but every attempt should be made to avoid
its use (Brodie & Bacchetta, 2011). For example, in the setting of chronic heart failure, patients
should undergo a VAD implantation, or organ transplant prior to any further substantial decline.
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This is similarly accurate where patients experience myocardial infarction and whose
cardiogenic shock is recognized early. Likewise, primary care centers should consult referral
centers to confer about patients on a case-by-case basis. Patients should be referred prior to any
dramatic hemodynamic deterioration where ECMO is the only solution. Overall, this type of
practice will lead to improved outcomes (Brogan et al., 2017).
2.7

Complications and Potential Negative Outcomes of ECLS

ECLS is a complex, interprofessional task where many theoretically grave complications
may occur. Such difficulties arise either directly or indirectly to capital equipment, the circuit, or
necessary medications. Exact complication rates are problematic to determine given the
conglomeration of wildly varying definitions used across literature. Additionally, the unreliable
reporting of complications intensifies the issue. Such adverse occurrences span from being more
trivial to catastrophic (Brodie et al., 2019). Among the most common complications, we see
bleeding, blood stream infections (BSI), hemolysis, infection, limb ischemia, and neurologic
events. Regardless of the modality, ECMO is linked with neurologic and pulmonary
complications that impact survival rates (Brogan & Annich, 2018).
2.7.1

Bleeding

Bleeding is recognized as the most recurrent and serious obstacle in ECMO, reported in
almost 34% for adult VA-ECMO according to the ELSO registry. (ELSO, 2015) According to
Brogan and Annich (2018), massive hemorrhaging is the greatest complication, with a reported
incidence of 30% to 42% among all ECLS patients with 25% to 63% of those requiring operative
resolution.
Brogan et al. (2017) continues, citing that blood loss complications produce noteworthy
morbidity and mortality rates within the ECLS patient population. ECMO patients are
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anticoagulated and inclined to bleed. For optimal blood oxygen saturation, hemoglobin levels
should be preserved between 8 and 10mg/dL. Point of care testing revealing levels below that
may require transfusion. Excessive bleeding is often treated by decreasing the anticoagulant
dosage (Guglin et al., 2019).
Noteworthy bleeding may be ascribed to the systemic therapeutic anticoagulation
mandatory to thwart clot formation. An acquired coagulopathy due to the blood’s exposure to
artificial surfaces and shear stresses, as well as any trauma induced by potentially invasive
procedures. Hemorrhage management necessitates harmonizing the control of bleeding with the
continued jeopardy of ECLS associated circuit thrombosis and possible thromboembolism
(Brogan et al., 2017).
Bleeding may manifest in the mouth, nose, and throat where although potentially
minimal, it may can be continuous. Additionally, bleeding is common from all catheters, IV
lines, and probes, regardless of their point of entry. Brogan and Annich (2018) states that
intracranial bleeding is a source of bleeding in 3% to 8% of all ECMO patients. It is important to
assess the patient for any signs of intracranial hemorrhage by looking at pupillary response and
level of consciousness. Additionally, it is fundamental to observe the lung secretions, gastric
lavage, stool, and urine output for the presence of blood (Brogan et al., 2017).
To avert bleeding, stringent control of hemostasis is necessary. The sensitive balance
between anticoagulants and procoagulants must be fully understood by those managing patients
on ECMO. Guglin et al. (2019) discusses several reports which authors advocate safety in
withdrawing all anticoagulation therapy for up to three days without significant risk imposed to
the patient. Brogan et al. (2017) notes that in conditions of life-threatening, active bleeding,
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anticoagulation should be discontinued and potentially reversed using antifibrinolytics, blood
products, and lastly protamine.
2.7.2

Blood Stream Infections

Definitions from the Centers for Disease Control (CDC) and National Healthcare Safety
Network (NHSN) were used to used when identifying blood stream infections (BSI). BSI is
defined as two separate positive blood cultures each containing a pathogenic organism and signs
of infection including fever, hyperthermia, leukocytosis, or leukopenia (Menaker et al., 2019).
Menaker et al. (2019) continues stating bloodstream infection is associated with mortality
of around 25% and it is found that in critically ill patients diagnosed with cardiovascular disease
the mortality rate is as high as 50%. Patients requiring ECMO are at risk for bloodstream
infection for several reasons. First, cardiogenic shock increases the risk for infection. Second, in
both VA- and VV-ECMO, patients require large indwelling cannulas that cannot simply be
replaced if they become infected, and third, ECMO patients frequently require a CVC for
vasoactive drugs and indwelling arterial catheters used for hemodynamic monitoring; both of
which raise the risk of bloodstream contamination (Brogan & Annich, 2018).
Blood stream infections are common in ECMO patients and although not associated with
in-hospital mortality rates, these infections were causative of increased reports of organ failure.
The microbiology of BSI in ECMO patients may differ from that of other patients in an ICU
(Menaker et al., 2019).
2.7.3

Hemolysis

Hemolysis may arise due to the constant trauma inducing whirling of blood cells
throughout the ECMO circuit (Gravlee et al., 2016). This environment may cause the red blood
cells (RBC) to break, constructing a potential for bleeding and subsequent loss of various blood
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components. Prior to present clinical signs being observed, initial detection is made possible by
measuring free plasma hemoglobin which typically presents with a reduction in platelet and red
blood cell counts. Hemolysis produces a distinctive diluted red hue in urine (Brogan & Annich,
2018). Lacking suitable treatment, the patient may develop disseminated intravascular
coagulation (DIC). Therapy consists of administering a variety of blood products including fresh
frozen plasma (FFP), platelets, and RBCs, as well as consideration for ECMO circuit
replacement (Brogan et al., 2017).
2.7.4

Infections

Risk for developing infections during ECLS therapy comprised of advanced age, duration
of treatment, increased disease severity, and mechanical complications. (Guglin et al., 2019)
According to Brogan and Annich (2018), the most common sources of infection include
bacteremia, bladder catheters, surgical wounds, vascular access, and wound infection.
Guglin et al. (2019) declares the most likely infectious complications of ECMO are
bacteremia and sepsis, with higher infection rates being associated with lengthier ECMO runs.
They also report that greater than 53% of adults obtain an infection within fourteen days of
initiating ECMO. Mortality rates up to 60% have been associated with patients diagnosed with
active infections.
Infection risk is increased for those on ECMO, especially those who are centrally
cannulated, where the cannula directly accesses the heart. Peripheral cannulation is a regular
source of infection (Brogan et al., 2017). Considering the urgent nature of ECMO insertion, it is
easy to associate the absolute importance of sterile technique during cannulation (Guglin et al.,
2019).
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The patient’s nurse should frequently assess the cannula insertion sites and the integrity
of the dressings. Monitoring for bleeding, redness, and swelling, in addition to any potential
infection should be regular practice (Brogan et al., 2017). Signs of infection include
hypotension, leukocytosis, tachycardia, tachypnea, temperature fluctuations, third spacing,
thrombocytopenia and vasodilation (Brogan & Annich, 2018).
2.7.5

Limb Ischemia

Historically, limb ischemia occurred in 16.9% of patients supported by peripheral VA
ECMO. Fasciotomy, due to compartment syndrome, was needed in 10.3% of patients, with
4.7% requiring amputation. Characteristic indications of limb ischemia are comprised of a loss
of pulses, pallor, or gangrene (Brogan et al., 2017). Compartment syndrome is not commonly
seen in intensely ischemic limbs prior to reperfusion, when a distal perfusion catheter is utilized.
However, following reperfusion, the affected limb may become edematous causing the skin to
become taut. If a measurement of the compartment pressures proves higher than 20 mmHg, a
fasciotomy is generally essential (Guglin et al., 2019).
Partial or total femoral artery occlusion may be caused by the ECMO return cannula. To
avert limb ischemia, it is suggested that a reperfusion cannula be placed in the superficial
femoral artery to provide adequate distal limb perfusion. The nurse should monitor the condition
of the leg by comparing the any development of blisters, coloration, and temperature, of both
legs as well as any evidence of foot necrosis. It is imperative that the reperfusion cannula and
line always be visible through a translucent dressing, so the nurse can observe the condition of
the site, and ensure there is an absence of clots, fibrin, or kinks (Borgan & Annich, 2018).
Similar conditions may occur with axillary cannulation, and a reperfusion line may be placed to
provide satisfactory perfusion to the affected arm (Brogan et al., 2017).
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2.7.6

Neurologic Complications

Reported rates of acute neurologic complications vary wild widely between 2% and 50%,
with the ELSO registry reporting seizures in 2% and acute intracranial hemorrhage in another
2% of adult patients receiving cardiac ECLS (Brogan et al., 2017; ELSO, 2016).
Both hemorrhagic and ischemic strokes occur in roughly 4% of VA-ECMO patients. The
frequency of stroke differs by cannulation technique and by indication. Ischemic stroke is most
common in ECPR patients, being found in 7% of successful resuscitations (Brogan et al., 2017).
Canulation via the carotid artery triples the risk of his of ischemic stroke compared with the with
femoral artery cannulation (Brogan & Annich., 2018).
The root cause of stroke is multifaceted; hemodynamic instability, systemic
anticoagulation, and other thromboembolic events are all acknowledged as contributing factors
(Guglin et al., 2019). Guglin et al. (2019) continues to explain that common place issues
regarding low blood flow rates can cause spontaneous formation of thrombi within the left
atrium (LA) and left ventirucle (LV). Secondarily, the circuit is subject to inadvertently
introducing bubbles, emboli, or particles (Gravlee et al., 2016).
2.7.7

Patient Monitoring

When monitoring ECMO, it is crucial to monitor values such found arterial blood gases,
or maintaining a watchful eye regarding differential hypoxia, extremity perfusion, left and right
ventricular function, preload, and venous oxygen saturation. Monitoring during ECMO
necessitates an understanding of the physiological foundation for the monitor’s validity (Guglin
et al., 2019). Employing data such as conventional vital signs like blood pressure, heart rate, and
urine output impose substantial limitations, as accuracy may be invalid, or prove ambiguous.
However, an intensivist may still wish to utilize this data for the purpose of adjudicating the
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adequacy of perfusion (Krishnan & Schmidt, 2019; Guglin et al., 2019).
The ECMO circuit must be checked at least daily. Any existence of thrombi in the
circuit, oxygenator, or pump head indicates lacking anticoagulation (Brogan & Annich, 2018).
For example, the auscultation of friction noise from the pump head may confirm an increased
fibrin deposition on the impeller blades. It is also recommended to regularly perform an
oxygenator “sigh”, in which the sweep gas is briefly dramatically increased to remove any water
condensation found within the oxygenator. This action will improve the oxygenator’s gas
exchange performance (Romano et al., 2017).
2.7.8

Thrombosis and Related Complications

Systemic anticoagulation lessens the interaction between blood and the surface of the
ECMO circuit. Albumin and fibrinogen are found to have been absorbed into the circuit’s
biopolymer components, resulting in platelet aggregation, activation, and consumption within
one hour of ECMO initiation (Abrams et al., 2016). Guglin et al. (2019) explains that the
instigation of the clotting cascade may result in thrombocytopenia which may be profound,
ultimately dictating platelet transfusions.
The bio-coating found on the inside surfaces of the ECMO circuit contains heparin,
which provides adds limited defense against excessive clotting. Supplementary anticoagulation
is essential to avert increased clot formation within the ECMO circuit. This will aid in the
prevention of thrombosis in the circuit’s cannulas, consequently circumventing dysfunction of
the oxygenator, hemolysis, and pulmonary embolism (Brogan et al., 2017). Between 10% and
33% of all patients treated with ECMO support experience hemorrhagic or thrombotic events.
Monitoring of anticoagulation may wildly vary according to the experience and preferences of
each ECMO center (Romano et al., 2017).
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In July 2015, ELSO’s International Registry Report acknowledged thrombi in nearly 40%
of all ECLS runs spanning all age groups and types of ECMO. The oxygenator was cited as
being the local of the highest number of reported clots (ELSO, 2015). Inadequate
anticoagulation, low flow states, and patient hypercoagulability are all contributory to an
increased danger of thrombosis (Brogan et al., 2017).
Heparin is the most utilized anticoagulant agent, used in accordance to the standard
weight-based protocol. It is generally monitored either by activated thromboplastin time (PTT),
with a goal of 50 to 75, or anti factor Xa, goal 0.3 to 0.7 IU/mL. Some facilities prefer to survey
the ACT due to it being readily available at the bedside and having a rapid turnaround time
(Guglin et al., 2019).
2.7.9

Volume Regulation

Throughout an ECMO run, the patient’s disease process and therapeutic treatment will
inevitably disturb their intravascular volume. It is vital to understand that the inferior vena cava
(IVC) will frequently exhibit rhythmic collapse during periods of coughing, respirations, or even
suctioning (Brogan et al., 2016; Brogan & Annich, 2018).
Save there is venous engorgement whereas the cannula does not meet the vascular lumen,
there will be partial cannula occlusion in many patients along the lateral fenestrations of the
cannula. This condition will cause brief periods of suck down or “chattering”, recognized by a
water hammer effect in the circuit, and a significant reduction in ECMO blood flow rates where
flows are acutely dropped by more than one or two liters per minute. This is considered
dangerous, as it can result in hemolysis, and, at worse, cavitation of air within the pump and air
embolization (Brogan & Annich, 2018; Tonna et al., 2021).
Although chattering may be eliminated by cautious administration of fluid or reduction of
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flow, when feasible, gratuitous fluid administration must be avoided (Tonna et al., 2021).
The capability of the ECMO circuit to provide the necessary gas exchange is reliant on
appropriate blood flow through the oxygenator. The goal of fluid management throughout
ECMO treatment is to ensure adequate vascular volume allow ECMO flow to propagate the
wanted degree of gas exchange. Virtually, this means most patients require fluid resuscitation
following the initiation of ECMO (Tonna et al., 2021).
Studies now boast that a negative fluid balance is congruent with better outcomes.
Therefore, the most reliable current data suggests that after the initial resuscitation phase of
ECMO, that whenever hemodynamically possible, caregivers should maintain a negative fluid
balance until the patient reaches their dry weight (Tonna et al., 2021).
2.8

Futility of Therapy and Ethical Considerations

The anticipated period of ECLS support is dependent on a multitude of factors, and
extremely individual per patient, however, among various published studies, most ECMO runs
span nine to fourteen days, while some may necessitate periods over four weeks (Tonna et al.,
2021).
Most ethical or moral challenges arising throughout ECLS are not limited to the
technology but are frequently overstated by the severity of the patients’ sickness. Critical ethical
matters include defining when refusal of treatment is proper, or whether withdrawing treatment
is acceptable when the hopes of care are no longer be feasible (Brodie et al., 2019).
Tonna et al. (2021) discusses when consideration should be given to end ECMO. First, it
is noted that the possibility of ending treatment for futility should be explained to the family
before ECMO is initiated. It is imperative that clear expectations are understood early on during
a course of ECMO. It was concluded that if there is not a reasonable level of sureness for the
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meaningful recovery, or bridge to transplant is possible, that stopping for futility must be
discussed.
In time, prior experience, or empirical evidence demonstrate ECLS will not allow for
meaningful survival, stopping is ethically appropriate (Brogan & Annich, 2018). In North
America, forgoing life sustaining therapies altogether, or desiring discontinuation of lifesustaining treatments such as artificial nutrition or hydration, dialysis, or mechanical ventilation
are both ethically and legally permissible. This is true even if these interventions are highly
beneficial, or even potentially life prolonging. When withdrawal becomes appropriate, frequent
discussions between the team and family should occur to foster understanding and prepare the
family; it should not come as a surprise (Brogan et al., 2017). Tonna et al. (2021) remarks that
because nearly one third of adult patients on support may not be able to be appropriately weaned,
the relevance of treatment should be regularly reviewed and should only be continued if a
reasonable chance of positive outcome remains. If there is not, organ donation post withdrawal
should be considered.
2.9

ECLS Team Members and Responsibilities

Procedures and protocols must be in place to alleviate stress, improve practice strategies,
and support all team members in this highly charged environment. Communication must be
clear, concise, and be shared with all team members. This will permit all team members to have
a clear understanding of the patient care plan (Brogan & Annich, 2018).
Communication and coordination between allied health staff, medical, and nursing team
members is congruent with quality ECMO outcomes (Shekar et al., 2020). A fully trained
multidisciplinary ICU team should be proficient in initiating and managing ECMO support
(Romano et al., 2017).
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Patients requiring ECMO demand the uppermost levels of intensive care from a
multidisciplinary team. Since the initiation of ECMO therapy is usually time sensitive,
numerous interventions take place in rapid succession or even simultaneously until the patient’s
condition is steadied (Brogan & Annich, 2018). A full assessment and triage by ECMO experts
to approve appropriate candidates is obligatory to avoid futile application of the therapy. Core
ECMO teams generally consist of dedicated and specifically trained physicians, an ECMO
coordinator, perfusionists, ECMO specialists, nurses, as well as respiratory therapists (Guglin et
al., 2019).
2.9.1

Perfusionist

The perfusionist will select the cannulas and set up and prime the ECMO circuit. Once
fully prepared, the perfusionist assists with initiating support. The perfusionist may be a key role
in continuous management and monitoring of the patient. However, perfusionist involvement
may be limited due to call expectations, manpower shortages, and OR workload. In the
circumstance that a perfusionist is unavailable to fulfill a bedside monitoring role, certified adult
ECMO specialists (CES-A) should be considered and dispatched to assume the management role
(Brogan et al., 2017; Brogan & Annich, 2018).
2.9.2

ECMO Specialist

The CES-A role is a team member who is adequately and expertly trained in all aspects
of ECMO monitoring and management. They are trained in identifying and managing the
complications of bleeding, infection, and mechanical failure of ECMO components. Ongoing
education and training are crucial to ensure that clinical competence and skill is maintained to
the highest standards to minimalize these risks. Attention to detail, communication skills, and
overall vigilance is paramount (Brogan & Annich, 2018).
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2.9.3

Nursing

ECMO support necessitates nursing at a 1:1 or 1:2 ratios, and ECMO physicians should
be immediately available in order provide continuous medical management (Guglin et al., 2019).
Teams are encouraged to maintain a senior specialist without a patient assignment to act as a
float for emergency contingency management, or as an extra set of hands as necessary (Shekar et
al., 2020).
Bedside nursing management of ECLS patients plays an essential role in positive patient
outcomes. The primary nurse is regularly considered the care coordinator. Additionally, they are
frequently the initial identifier and resolution initiator regarding any complications (Brogan et
al., 2017).
2.10 ECLS Standardization

Despite exponential growth in ECLS, standardization is deficient across each facility, region, and
even country. Ultimately, the ideal methods to management are unknown. For example, there is
no consensus on the most suitable approach for delivering and measuring anticoagulation during
ECLS. Additionally, there is an imperfect comprehension of the effect of the circuit on
pharmacokinetics. Furthermore, appropriate echelons of blood flow and sweep gas rates are
undecided, in part because ideal targets for oxygenation and ventilation vary, as do every patient,
and their etiologies (Brodie et al., 2019).
There is an increasing evidentiary body that advocates ECMO has a significant role in
bridging judiciously chosen patients to lung transplantation at centers with expertise in both.
Cannulation and treatment strategies that facilitate an awake and extubated approach to
maximize physical therapy can optimize post-transplant outcomes (Brogan et al., 2017).
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Grant et al. (2018) says the progression in technology and familiarity of complex
physiologies associated with these critically ill patients are beginning to validate improved
outcomes. Uniform ECMO processes are imperative to provide a common vernacular,
consistency in therapy, facilitate research, and improve outcomes.
2.11 Cost of ECLS

ECLS is costly, with the expenditures varying accordingly to each geographic region.
Due to this variation, the need for real-world data demonstrating expenses of facilitating ECLS
to educate governments, health care institutions, and policy makers (Brodie et al., 2019).
As of 2017, Romano et al. stated that considering the then current equipment costs in
Brazil, were between $8,000 and $36,000 per patient. Romano et al (2017) continues asserting
that the cost of efficacy per quality adjusted life year (QALY) is sensible within developed
countries, and that it may be tolerable in Brazil.
It is projected that approximately 2 million people with acute respiratory failure are
hospitalized each year within the United States at a cost exceeding $50 billion (Brodie et al.,
2019). One is left to question whether continued development and implementation of ECMO
may reduce the overall expenditures for such ailments.
2.12 Summary

With the continued advancements of new ECLS technologies comes the promise of
increasing opportunities to treat respiratory failure; the role of ECLS will no doubt continue to
cultivate the necessity for high-quality research (Brodie et al., 2019).
Brodie et al. (2019) Carefully warns that the continuous evolution of ECMO should not
be considered a summons to free will, or unlimited and unrestrained use of the treatment. While
the role of ECLS is ever growing, thoughtfulness must be taken not to permit enthusiasm to seal
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the gaps in evidentiary practice. Thus, we propose to examine a representative sample of ECMO
patients to evaluate current practice and cost using administrative hospital billing data.
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3
3.1

CHAPTER III: METHODOLOGY

Research Design or Method
We will use a descriptive retrospective cohort design to examine the in hospital

characteristics of a representative sample of ECMO patients. Patient level personal, disease, and
cost characteristics will be described.
3.2

Study Aims
The aim of this study is to describe current patient and hospital characteristics of patients

hospitalized on ECMO.
3.3

Sample Selection
A sample of all ECMO patients hospitalized in the state of Florida in the year 2018 will

be used to perform this study.
3.4

Data Set Description
The 2018 sample of Florida ECMO patients from the Healthcare Cost and Utilization

Project (HCUP) sponsored by the Agency for Healthcare Research and Quality (AHRQ). The
HCUP Florida State Inpatient Database (SID) will be used in this study in order to be able to
follow patients for readmission measurement.
3.5

Cohort Identification
ECMO patients will be identified using DRG procedure codes listed in Table 1.
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3.6

Independent and Dependent Variables
Independent variables include;
1. Age
2. Charleson Comorbidity Index
3. Race
4. Sex
5. Type of ECMO; VA or VV
Dependent oucome variables include;
1. 30-day readmission
2. Hospital length of stay
3. Per day cost of hospitalization
4. Total cost of hospital stay

3.7

Data Analysis
Statistical analysis will be performed using SAS version 9.4 software (Cary, NC).

Descriptive statistics will be reported using mean and standard deviation (median and
interquartile range when appropriate) for continuous measures and frequencies and percentages
for categorical variables. Generalized linear models will be used to estimate each outcome while
controlling for the independent covariates listed in the prior section. If the outcome is
dichotomous, Logistic regression will be used. If the outcome is a count variable (ex: days in
hospital) a linear regression using a negative binomial distribution with log link will be utilized.
For cost outcomes a linear regression using a gamma distribution with log link will be used.
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3.8

Protection of Human Subjects
The institutional review board of MUSC have deemed the data used in these analyses to

be non-human research.
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4
4.1

CHAPTER IV: RESULTS

Clinical Characteristics
Table 1 describes the clinical characteristics of those included within the study. In total,

there were 14,960 patients placed on ECMO in Florida, during the fourth quarter of 2018. Of
those, 13,664 (91.3%) required VA support, while the remaining 1,296 (8.7%) needed VV
support.
Results were created by utilizing the Diagnosis-Related Group (DRG) codes billed for
when the patient was discharged on their initial discharge. DRG code changes were updated and
implemented for fiscal year 2019 and took effect 1 October 2018. Data showed that the majority
of ECMO treatments occurred in Q4, once the new DRG codes were implemented. The four
codes considered were a). 207: Peripheral ECMO for Respiratory Failure, b). 291: Peripheral
ECMO for Heart Failure, c). 296: Peripheral ECMO for Cardiac Arrest, and d). 870: Peripheral
ECMO with Sepsis. ECMO for heart failure (291) was noted to be the largest cause of ECMO
use with 12,542 (83.8%) patients of the cohort requiring it which simultaneously represents
91.8% of the VA ECMO patients. The remaining 1,122 (7.5%) of VA ECMO patients were
coded for respiratory failure in the 207 DRG. Approximately eighty-eight percent (87.5%) or
1,134 of the VV patients were coded with the sepsis DRG code of 870, while the remaining 162
or 12.5% were identified by the 296 DRG code for peripheral ECMO for cardiac arrest.
Initial discharge or transfers were broken down into seven categories. The largest number
of patients discharged came to a total of 5,639 (37.7%) of the cohort, who were discharged to
their home. This was followed by 3,430 (22.9%) being discharged into the care of a home health
service provider. A total of 2,342 patients comprising of 15.7% of the cohort were discharged to
a skilled nursing facility. Lastly there were nearly equal proportions of individuals discharged to
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TABLE 1: Clinical Characteristics
Characteristic
n
DRG on Initial Discharge

Value

Overall
14,960

VA
13,664

VV
1,296

207ᵃ
291ᵇ
296 ᶜ
870 ᵈ

1,122 (7.5)
12,542 (83.8)
162 (1.1)
1,134 (7.6)

1,122 (8.2)
12,542 (91.8)
-

162 (12.5)
1,134 (87.5)

Home
Home Health
Hospice
Skilled Nursing Facilty
Other Facility
Expired
Other

5,639 (37.7)
3,430 (22.9)
1,162 (7.8)
2,342 (15.7)
1,037 (6.9)
1,016 (6.8)
334 (2.2)

5,540 (40.5)
3,346 (24.5)
870 (6.4)
2,151 (15.7)
853 (6.2)
587 (4.3)
317 (2.3)

99 (7.6)
84 (6.5)
292 (22.5)
191 (14.7)
184 (14.2)
429 (33.1)
17 (1.3)

18-44
45-64
65-79
80+

584 (3.9)
3,331 (22.3)
5,476 (36.6)
5,569 (37.2)

476 (3.5)
2,911 (21.3)
4,979 (36.4)
5,298 (38.8)

108 (8.3)
420 (32.4)
497 (38.3)
271 (20.9)

Male

8,048 (53.8)

7,372 (54.0)

676 (52.2)

Black
Hispanic
White
Other

3,088 (20.6)
2,178 (14.6)
9,295 (62.1)
399 (2.7)

2,856 (20.9)
1,991 (14.6)
8,465 (62.0)
352 (2.6)

232 (17.9)
187 (14.4)
830 (64.0)
47 (3.6)

1,055 (7.1)
1,106 (7.4)
11,990 (80.2)
809 (5.4)

938 (6.9)
955 (7.0)
11,070 (81.0)
701 (5.1)

117 (9.0)
151 (11.7)
920 (71.0)
108 (8.3)

13,664 (91.3)
6,732 (45.0)
976 (6.5)
3,730 (24.9)
5,628 (37.6)
2,231 (14.9)
734 (4.9)
2,976 (19.9)
9,279 (62.0)
475 (3.2)

13,090 (95.8)
6,219 (45.5)
797 (5.8)
3,324 (24.3)
5,327 (39.0)
1,998 (14.6)
582 (4.3)
2,862 (20.9)
8,839 (64.7)
429 (3.1)

574 (44.3)
513 (39.6)
179 (13.8)
406 (31.3)
301 (23.2)
233 (18.0)
152 (11.7)
114 (8.8)
440 (34.0)
46 (3.5)

3.9 ± 1.6
4.0
[3.0 - 5.0]

4.0 ± 1.5
4.0
[3.0 - 5.0]

3.1 ± 2.2
3.0
[2.0 - 4.0]

Initial Discharge/Transfer Status

Age Groups

Sex
Race

Payer

Commercial
Medicaid
Medicare
Other
Charlson Comorbidity Index (by Category)
Congest Heart Failure
Chronic Pulm Disease
Cardiovascular Disease
Diabetes
Diabetes Complication
Myocardial Infarction
Mild Liver Disease
Pulm Vascular Disease
Renal Disease
Rheumatic Disease
Charlson Comorbidity Index (Continuous)

All values expressed as n(%), mean ± s.d., and median [Q1 - Q3]
ᵃ ECMO for Respiratory Failure
ᵇ ECMO for Heart Failure
ᶜ ECMO for Cardiac Arrest
ᵈ ECMO with Sepsis
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p-value
<0.0001

<0.0001

<0.0001

0.22
0.01

<0.0001

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.01
<0.0001
<0.0001
<0.0001
0.42
<0.0001

either another facility or hospice care were 1,037 (6.9%) and 1,162 (7.8%) respectively. A total
of 1,016 or 6.8% expired. The VA group had a higher proportion who went home or home to
home health and VV group had a much larger proportion who expired or were discharged to
hospice (p <0.0001).
Age groups were established and broken down into four categories. Overall, only 584
(3.9%) of the cohort were between the ages of 18 and 44. Of those, 476 (3.5%) were on VA
while 108 or 8.3% required VV ECMO. Those categorized in the 45-64 year-old group
numbered 3,331 (22.3%) of the cohort. In that group, 2,911 (21.3%) received VA ECMO, while
420 or 32.4% were on VV ECMO. There were 5,476 or 36.6% individuals who fell into the age
range of 65-79 years old, of which 4,979 or 36.4% of the cohort needed VA ECMO, and 497
(38.3%) required VV ECMO. In total, 5,569 (37.2%) of the study were aged more than 80 years.
Of those, 5,298 or 38.8%, required VA ECMO, and only 271 (20.9%) needed VV ECMO. The
VA ECMO group were, on average, older when compared with the VV group (p<0.0001).
Considering gender, it was noted that 8,048 (53.8%) of the cohort were men. Of those
men, 7,372 or 54.0% needed VA ECMO, while 676 (52.2%) men were placed on VV ECMO,
these were not statistically different (p=0.22).
The cohort was broken down into four racial categories: black, Hispanic, white, and
other. Black patients made up 3,088 or 20.6% of the cohort. Within that category, 2,856, or
20.9% of them received VA ECMO, and the remaining 232 or 17.9% were placed on VV
ECMO. Hispanics numbered a total of 2,178 (14.6%) where 1,991 (14.6%) and 187 (14.4%)
required VA and VV ECMO respectively. The other group was relatively small, comprising of
399 (2.7%) of the cohort. There were 352 (2.6%) of that group needing VA ECMO, while 47
(3.6%) were placed on VV ECMO. The largest group in that category were represented by a
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white population. Sixty two percent (62.1%) of the cohort, or 9,295 patients were white. Of that
number, 8,465 or 62.0% received VA ECMO. The remaining 830 (64.0%) required VV ECMO.
The VA group had a statistically higher proportion of minorities when compared with
individuals on VV (p=0.01).
When analyzing payers, the cohort was divided by four categories: commercial,
Medicaid, Medicare, and other. The largest number of patients were covered by Medicare,
totaling 11,990 (80.2%) of the cohort. The remaining three categories were close and similar in
nature. Medicaid insured 1,106 (7.4%), commercial coverage paid for 1,055 (7.1%) and there
were 809 (5.4%) that fell into the remaining other category. Medicare’s distribution showed
11,070 (81.0%) on VA, and 920 (71.0%) VV ECMO patients. Medicaid resulted in 955 or 7.0%
requiring VA, while 151 (11.7%) received VV ECMO. Commercial payers saw 938 (6.9%) on
VA ECMO and 117 or 9.0% on VV. A larger proportion of the VA were on Medicare than the
VV (p <0.0001).
On average, the Charlson Comorbidity Index Score was higher in the VA group (4.0 ±
1.5) compared with the VV group (3.1 ± 2.2) (p <0.0001). Individual subcategory Charlson
Scores can be found in Table 1. Many of the subcategory scores were different between the
comparison groups and coincided with the definitions related to the DGR groups that likely
influenced their need for either VA or VV ECMO.
4.2

Unadjusted Outcomes
The unadjusted outcomes can be found in Table 2. The proportion of deaths which

occurred during their ECMO hospitalization numbered 1,016, or 6.8% of the cohort. Of that
number, 587 (4.3%) were receiving VA ECMO support and 429, or 33.1% were on VV support
(p<0.0001).
48

Table 2: Unadjusted Outcomes
Characteristic
Overall
n
14,960
Death during ECMO hospitalization
1,016 (6.8)
Total Cost
$15,245 ± $24,226
$7,807
[$5,021 - $14,957]
Cost Per Day
$2,118 ± $1,294
$1,893
[$1,419 - $2,621]
Length of stay, days
7.3 ± 10.6
4.0
[3.0 - 8.0]
30-day Readmission rates
2,111 (14.1)
30-day ECMO Readmission rates
192 (1.3)

VA
13,664

VV
1,296

587 (4.3)

429 (33.1)

$12,904 ± $22,216
$7,271
[$4,817 - $12,148]

$39,931 ± $30,076
$33,653
[$22,337 - $49,578]

$2,111 ± $1,176
$1,821
[$1,382 - $2,466]

$3,373 ± $1,839
$3,010
[$2,316 - $3,852]

6.7 ± 10.1
4.0
[3.0 - 7.0]

13.9 ± 13.0
12.0
[7.0 - 17.0]

1,999 (14.6)

112 (8.6)

187 (1.4)

5 (0.4)

p-value
<0.0001
<0.0001

<0.0001

<0.0001

<0.0001
0.0027

All values expressed as n(%), mean ± s.d., and median [Q1 - Q3]

In unadjusted analysis of total ECMO hospital cost the overall group mean cost was
$15,245 (SD $24,226). However, when comparing the total hospital costs between groups we
found a $27,027 higher mean cost in the VV group (Mean $39,931, SD $30,076) compared with
the VA (Mean $12,904, SD $22,216) group (p-value <0.0001).
The unadjusted cost per day for the cohort was $2,118 (SD $1,294). The VV group
demonstrates a mean cost of $3,373 (SD $1,839) which is a $1,262 higher cost per day than that
of VA ECMO group (Mean $2,111, SD $1,176; p-value <0.0001).
Unadjusted outcomes for length of stay show mean of 7.3 (SD 10.6) days for the overall
group. The VA patients, experienced a mean of 6.7 days (SD 10.1) while the VV patients
number of days were nearly doubled with a mean of 13.9 days (SD 13.0) (p-value <0.0001).
Fourteen percent (14.1%), or 2,111 cohort members were readmitted to a hospital facility
within thirty days of initial discharge. Of those readmitted, 1,999 or 14.6% of VA subjects
required readmission. The VV group had an 8.6% readmission rate, compared to the VA group’s
14.6% (p-value<0.0001).
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When looking at 30-day ECMO readmission, 192 (1.3%) of the cohort needed subsequent
ECMO therapy. Of that number, 187 (1.4%) of cohort received VA treatment upon readmission.
The remaining 5 (0.4%) necessitated VV intervention (p-value=0.0027).
4.3

Adjusted Outcomes
The average adjusted total cost of ECMO hospitalization was $16,013 for the VA group

compared with $42,978 for the VV group resulting in a marginally higher hospital cost for the
VV patients $26,965 higher than the VA group (p-value <0.0001). FACTORS factors were also
controlled for when calculating the average ECMO length of stay. The VA group on average
stayed for 10.0 days, while the VV group’s stay was 19.0 days, a difference of 9.0 days (p-value
<0.0001).
The average adjusted cost per day of ECMO hospitalization was $2,237 for the VA
group, while the VV group’s average was $3,114 (p-value <0.0001), while controlling for age
group, death, payer, race, sex, and the Charlson Comorbidity Score.
Results from multivariable logistic regression 30-day modeling the odds of readmission
results are displayed in Figure 1. VA ECMO patients had 84% higher odds of being readmitted
than a VV ECMO patients (OR=1.84, 95% CI 1.50 – 2.25). When comparing age groups, the
18-44 year-olds were found to be 84% more likely to be readmitted when compared to the 80+
age group (OR=1.84, 95% CI 1.42 – 2.39). The 45-65 year-old group was 65.2% more likely to
be readmitted in the 30 days after ECMO hospitalization (OR=1.65, 95% CI 1.42 – 1.92).
Finally, the 65-79 year-old group experienced a 31.1% higher odds of readmission compared to
the 80+ year old group (OF=1.31,95% CI 1.17 – 1.47).
When comparing race, no significant statistical differences were observed.
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Figure 1: Adjusted odds of 30-day readmission

Men are noted to be 15% less likely to be readmitted within a 30-day period (OR=0.85,
95% CI 0.77 – 0.94).
Those covered by Medicaid were 53% more likely to be readmitted versus those
commercially insured (1.53, 95% CI 1.20 – 1.97). Similarly, patients covered by Medicare are
found to be readmitted at 53% higher odds than commercially insured (OR=1.53, 95% CI 1.24 –
1.90). Those categorized in the other group had 6.4% higher odds of readmission when
compared to those with commercial coverage (1.06, 95% CI 0.80 – 1.42), however this did not
reach statistical significance, so there is no difference in odds.
In adjusted analysis, for each Charlson comorbidity index point increase, there was an
increase in odds of 30-day readmission of 6% (OR=1.06, 95% CI 1.03 – 1.09).
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5
5.1

CHAPTER V: DISCUSSION

Discussion of Results
Discharge information was distributed as expected. Data showed that the largest group of

patients reaching 5,639 (37.7%) recovered and were discharged to home. The next largest group
of subjects numbering 3,430 (22.9%) were discharged to a home health service, followed by the
third largest group totaling 2,342 (15.7%) being admitted into a skilled nursing facility. The
remaining groups which included those who expired, discharged to hospice, or another facility
were all extremely similar in numbers.
Age groups appeared to be reflective of the aging population in Florida. This was
demonstrated by the exceptionally high numbers of patients receiving ECMO therapy who fell
into the group of 80 and older. This result may not be seen in other regions of the country.
Payer data meets expectations due to Florida population demographics. Considering the
age and retirement status of a large portion of Florida’s residents it is understandable that the
majority of patient’s in this cohort receiving ECMO treatment were covered by federal plans
versus private or commercial plans.
Charlson results were as expected, where comorbidities showed the highest portions of
the cohort being affected by congestive heart failure, renal and chronic pulmonary diseases,
followed by diabetics with complications.
Deaths during ECMO hospitalization were lower than anticipated for VA patients.
According to ELSO, between 2015-2019, 41% of VA patients expired compared to our cohort’s
587 (4.3%). During the same timeframe, ELSO reported a death rate of 31% in VV patients,
while our cohort experienced a slightly higher 33.1% (ELSO, 2020).
Costs were not as expected, in particular the adjusted cost per day which accounts for
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longer stays in the VV group. According to studies done by Hayden in 1993, costs then were
reported as $5,000 to $10,000 per day. In 2013, Zangillo et al. published costs falling between
$3,000 and $20,000 per day. There is no evidence in the literature that one would expect such
differences in LoS and cost between the VV and VA groups. In fact, clinically we consider the
VA group to be more complicated therefore would expect the differences to be reversed with the
VA group needing more care, longer hospitalizations, and overall being more costly.
Both readmission and ECMO readmission were lower than anticipated. However,
consideration should be made in regards to changes in advanced directives, care plans, wishes to
continue treatment, as well as death itself.
5.2

Limitations
Several limitations were noted within this study. Actual discharge dates, as well as precise

dates of patients being on ECMO were unable to be captured. This made discovering accurate
readmission data difficult. It must be considered that some readmissions may have fallen into
Q1 2019 which were not captured in the data.
DRG’s were updated and subsequently changed for fiscal year 2019. These changes took
place in Q4 FY 2019, beginning 1 October 2018. Questionable numbers were felt to have
significantly skewed the results of this study. The number of preceding DRG code 003 ECMO
billings in Q1 through Q3 totalled 3,996, averaging 444 ECMO cases per month for the entire
state of Florida. In Q4, the total number jumped to 14,960, or an average of 4,987 per month.
The number of ECMO cases billed for in Q4 reflects a number relative to ELSO’s reporting for
several years, not realistic for a 90-day period. Although it is believed that not each ECMO case
is captured and reported by ELSO, this was a staggering increase and caused hesitation early on
in the study. Upon further research, and after reanalyzing our data, it was determined that the
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numbers reflected the correct billing input. Further investigating, we discovered that the 291
DRG code had previously been labeled as “Heart Failure”. Upon the FY 2019 update, it was
changed to “Heart Failure with ECMO”. It is believed that this changed caused errors in billing
and that it was still being utilized for the previously used single heart failure diagnosis in
addition to those correct billings of ECMO. This allows us to make the assumption that all data
is incorrect and dramatically affects the validity of the numbers reported. This incorrect billing
code use will directly alter each aspect of this study; length of stay, outcomes, and overall costs,
as well as readmission rates. This may also account for the higher number of VA ECMO
participants and their better outcomes when compared to their VV ECMO counterparts.
5.3

Future Research
Future studies should scrutinize a full year’s worth of outcomes and confirm that

analogous trends exist over a longer period of time. This study should be revisited during a
timeframe that major DRG code changes are not implemented. Further research should also
consider a period of time beyond major changes to ensure that those changes are acknowledged
and properly utilized.
Furthermore, it would be recommended that a similar approach be taken with not only a
larger cohort, but concurrently include an assortment of states that supply a less varied
population in age and wellness. Florida patients potentially affect results due to it’s patient
population; their age, comorbidities, and insurance converage, all of which may be less diverse
in other areas of the country.
There is still a need to measure the overall costs of ECMO services. When costs can be
properly quantified, those results can be vital in determining a degree of efficacy, and potential
cost versus benefit analysis may be possible. In a world of ever increasing healthcare
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expenditures, and a perpetually declining degree of wellness in the United States this information
could be invaluable to hospital systems not only within the Unites States, but in other countries
worldwide.
5.4

Conclusions
ECMO is an ever-changing modality of potentially life saving therapy. As technology

and understanding continue to improve, so does its efficacy. Prompt assessment and
implementation must be achieved in order to give the patient the best outcome, ultimately
reducing expenditures and financial burden to payers of all varieties.
Access, costs, and patient viability must always be paramount considerations in a therapy
as arduous as ECMO. As the American population continues to age, and seemingly worsen in
wellness, we as clinicians only expect to witness an exponential increase in ECMO use.
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